New MHRA Export Guidance: Compliance Updates for UK Supplement Manufacturers
The MHRA has updated its guidance on exporting drugs and medicines, including specific provisions for certain raw materials and finished products. UK manufacturers must ensure robust licensing and certification processes to maintain market access and avoid supply chain disruption.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 06 May 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance for UK manufacturers exporting drugs and medicines, which critically impacts certain supplement categories. The revised regulations outline specific permissions required for controlled drugs, substances with potential dual-use (e.g., lethal injections), and general human or veterinary medicines. This affects not only finished pharmaceutical products but also nutraceuticals and some raw material ingredients that fall under these classifications, necessitating stringent compliance protocols for UK-based manufacturers and brand owners.
Exporters of controlled drugs must secure an export licence in addition to any domestic possession licences. The MHRA advises checking against a list of common controlled drugs and relevant legislation, placing the onus firmly on the exporter to verify classification accurately. For substances that could be used in lethal injections, a VMD export certificate application requires support from an export licence issued by the Export Control Joint Unit (Department for Business and Trade - DBT), which must be uploaded with the application.
For general medicines, manufacturers must proactively verify they possess a drug manufacturer, wholesale dealer, and marketing authorisation licence. Absence of these necessitates an application, significantly extending export timelines. An export certificate may also be required, with five types for human medicines (Certificate of a pharmaceutical product (licensed/unlicensed), Certificate of manufacturing status, Certificate of licensing status, Certificate for the importation of a pharmaceutical constituent) and five for animal medicines (Defra-1, Defra-2, Defra-3, Defra-4, Defra-SFA) detailed. Each type serves a distinct purpose, depending on the importing country's requirements and the product's status. For instance, the 'Certificate of a pharmaceutical product (unlicensed)' specifically demands proof of UK manufacture and a valid manufacturer licence.
What this means for United Kingdom
UK supplement manufacturers must conduct a comprehensive review of their product portfolios against the updated MHRA classifications, particularly for any ingredients that might trigger controlled substance or dual-use regulations. This regulatory tightening will increase compliance costs, requiring advanced planning for licence applications and certification, potentially extending reformulation windows by 3-6 months. Brand owners planning market expansion must factor in longer lead times for export documentation, impacting speed-to-market and competitive positioning in new territories. Procurement teams should verify supplier compliance to safeguard against upstream supply chain disruptions. Failure to adhere to these updated guidelines risks significant delays, product impoundment at borders, and reputational damage.
The process for obtaining an export certificate for human medicines involves submitting application forms to exports@mhra.gov.uk, or via the MHRA portal, along with necessary supporting documentation such as formulation details or letters of permission from marketing authorisation holders. Veterinary medicine export certificates are applied for online via the VMD portal, with processing typically within 10 days of application. Fees vary for animal medicine certificates, ranging from £30 to £54, influenced by the location of the manufacturing site (GB vs. NI) and the scope of the marketing authorisation. This fee structure adds nuanced cost considerations for manufacturers operating across different UK regions or holding divergent marketing authorisations.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.